LXEO supply chain intelligence for Lexeo Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Lexeo Therapeutics, Inc. (LXEO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| THE-REGENTS-OF-UNIVERSITY-OF-CALIFORNIA-SAN-DIEG | THE-REGENTS-OF-UNIVERSITY-OF-CALIFORNIA-SAN-DIEG | 92% | we obtained a license to materials and intellectual property related to a gene therapy for ARVC |
| STELIOS-THERAPEUTICS-INC | STELIOS-THERAPEUTICS-INC | 90% | The Company is required to pay up to a remaining aggregate of $ 12.5 million to the selling shareholders of Stelios upon the achievement of certain development milestones |
| DSGN | Design Therapeutics, Inc. | 72% | Reciprocal relationship from DSGN graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a… |
| DSGN | Design Therapeutics, Inc. | 72% | ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t… |
| LRMR | Larimar Therapeutics, Inc. | 72% | Reciprocal relationship from LRMR graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a… |
| LRMR | Larimar Therapeutics, Inc. | 72% | ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | Reciprocal relationship from NBIX graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified an… |
| PRME | Prime Medicine, Inc. | 72% | ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a… |
| PTCT | PTC Therapeutics, Inc. | 72% | ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t… |
| PTCT | PTC Therapeutics, Inc. | 72% | Reciprocal relationship from PTCT graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a… |
| SLDB | Solid Biosciences Inc. | 72% | Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from SLDB g… |
| SLDB | Solid Biosciences Inc. | 72% | ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t… |
| VYGR | Voyager Therapeutics, Inc. | 72% | Reciprocal relationship from VYGR graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a… |
| VYGR | Voyager Therapeutics, Inc. | 72% | ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CORNELL-LICENSE-AGREEMENTS-STELIOS-THERAPEUTICS- | CORNELL-LICENSE-AGREEMENTS-STELIOS-THERAPEUTICS- | 85% | pect to the right of reference, or the licensed data, know-how, or patent rights, with 90 days’ prior written notice to Cornell. On December 17, 2025, the Company executed a Second Amendment to the T… |
| SPACECRAFT-SEVEN-LLC | SPACECRAFT-SEVEN-LLC | 85% | dants downloaded confidential Rocket company documents and other proprietary materials prior to leaving Rocket in 2021 and that the Company used this information to advance its programs after they be… |
| DSGN | Design Therapeutics, Inc. | 72% | Reciprocal relationship from DSGN graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays … |
| DSGN | Design Therapeutics, Inc. | 72% | s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan… |
| LRMR | Larimar Therapeutics, Inc. | 72% | Reciprocal relationship from LRMR graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from LRMR graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from LRMR g… |
| LRMR | Larimar Therapeutics, Inc. | 72% | s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan… |
| NBIX | Neurocrine Biosciences, Inc. | 72% | Reciprocal relationship from NBIX graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays … |
| NBIX | Neurocrine Biosciences, Inc. | 72% | s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan… |
| PRME | Prime Medicine, Inc. | 72% | Reciprocal relationship from PRME graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from PRME g… |
| PRME | Prime Medicine, Inc. | 72% | s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan… |
| PTCT | PTC Therapeutics, Inc. | 72% | Reciprocal relationship from PTCT graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ul… |
| PTCT | PTC Therapeutics, Inc. | 72% | s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan… |
| SLDB | Solid Biosciences Inc. | 72% | s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan… |
| SLDB | Solid Biosciences Inc. | 72% | Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ul… |
| VYGR | Voyager Therapeutics, Inc. | 72% | s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan… |
| VYGR | Voyager Therapeutics, Inc. | 72% | Reciprocal relationship from VYGR graph: Reciprocal relationship from LXEO graph: s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays … |
| AMENDED-CORNELL-LICENSE-AGREEMENTS-STELIOS-THERA | AMENDED-CORNELL-LICENSE-AGREEMENTS-STELIOS-THERA | 62% | nell License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with 90 days’ prior written notice to Cornell. On December 17, 20… |
| FDA-REATA-PHARMACEUTICALS-INC | FDA-REATA-PHARMACEUTICALS-INC | 62% | ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t… |
| IN-CATALYST-PHARMS-INC | IN-CATALYST-PHARMS-INC | 62% | s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materially harmed. We have invested a significan… |
| REATA-PHARMACEUTICALS-INC | REATA-PHARMACEUTICALS-INC | 62% | ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on t… |
| STELIOS-THERAPEUTICS-INC | STELIOS-THERAPEUTICS-INC | 62% | nell License Agreement, in whole or in part with respect to the right of reference, or the licensed data, know-how, or patent rights, with 90 days’ prior written notice to Cornell. On December 17, 20… |
| TILIA-THERAPEUTICS-INC | TILIA-THERAPEUTICS-INC | 62% | ontinuing operations, if at all. 6 Risks and Uncertainties —The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not lim… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LXEO-DEBT-10838 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-12-31. |
| LXEO-DEBT | Debt stack $7.4M | 90% | Market cache reports total debt of $7.4M. |
| LXEO-DEBT-59476 | Warrants outstanding: 2446000 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LXEO-OWNER-JANUS-HENDERSON-GROUP-PLC | JANUS HENDERSON GROUP PLC | 90% | 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 139 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| MPLT | MapLight Therapeutics, Inc. | 100.00 | 2 | |
| INSM | Insmed Incorporated | 100.00 | 2 | |
| STQN | Strategic Acquisitions, Inc. | 100.00 | 2 | |
| SLNO | Soleno Therapeutics, Inc. | 100.00 | 2 | |
| PTCT | PTC Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| RARE | Ultragenyx Pharmaceutical Inc. | 100.00 | 2 | |
| NBIX | Neurocrine Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| MGTX | MeiraGTx Holdings plc | 100.00 | 2 | |
| SLDB | Solid Biosciences Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| RNA | Atrium Therapeutics, Inc. | 100.00 | 2 | |
| ETON | Eton Pharmaceuticals, Inc. | 100.00 | 2 | |
| SNYNF | Sanofi | 100.00 | 2 | |
| CLPT | ClearPoint Neuro, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| ALEC | Alector, Inc. | 100.00 | 2 | |
| MYGN | Myriad Genetics, Inc. | 100.00 | 2 | |
| SRPT | Sarepta Therapeutics, Inc. | 100.00 | 2 | |
| AARD | Aardvark Therapeutics, Inc. | 100.00 | 2 | |
| TRDA | Entrada Therapeutics, Inc. | 100.00 | 2 |